Low-dose testosterone for nonbinary people: what the data shows

What did @dudewheresmyssri actually say?

Shane, three months into low-dose subcutaneous testosterone (0.2mL weekly, via Lotus), logged a detailed personal update covering weight gain, mood changes, libido, body odor, skin, voice, hair, and sleep. They were upfront about having an eating disorder and acknowledged it likely contributed to gaining "at least 25-30 pounds." They described significant irritability, increased libido, new acne, a subtle voice drop with associated throat soreness, early leg and arm hair growth, higher daytime energy, and dramatically longer sleep needs. This is a first-person experience report, not a medical claim, and Shane presented it as such throughout.

Worth noting: Shane disclosed the eating disorder unprompted. That kind of transparency is rare in TikTok health content and actually matters clinically, because binge eating disorder and testosterone therapy can interact in ways most creators never bother to mention.

Does the science back this up?

Mostly, yes. The constellation of changes Shane describes at three months is consistent with what the peer-reviewed literature shows for low-dose testosterone in transmasculine individuals. The timeline and symptom pattern hold up.

On mood and irritability: a 2019 study by Nguyen et al. in Andrology found that testosterone initiation in transmasculine patients was associated with mood changes in both directions early in treatment, including increased irritability, particularly in the first several months as levels fluctuate. This is not unique to gender-affirming care. Men with hypogonadism starting TRT report similar short-term mood volatility (Walther et al., 2019, Psychoneuroendocrinology).

On libido: clitoral and labial tissue is highly androgen-sensitive. Increased libido within weeks to months is one of the most consistent and earliest reported effects across studies (Deutsch, 2016, UCSF Transgender Care). Shane's "month three" timing is right on schedule.

Voice changes with throat soreness during early masculinization are documented but underreported in clinical literature. The laryngeal cartilage is physically restructuring, and straining to hit lower registers before that process completes can genuinely cause discomfort.

What did they get wrong (or right)?

Shane got most of this right, with one area worth examining closely: the weight gain attribution.

Twenty-five to thirty pounds in three months is a significant amount, and Shane is honest that their eating disorder is likely a primary factor. But they also say "every week I'm also injecting this dose of testosterone so I'm sure those two factors are weighing heavily." The implication that low-dose testosterone is a meaningful driver of that scale of weight gain in three months deserves scrutiny.

Testosterone does influence body composition, primarily by promoting lean muscle mass and potentially redistributing fat. At a low dose, supraphysiologic weight gain as a direct testosterone effect is unlikely to account for 25-30 pounds in 90 days. That magnitude, in that timeframe, points primarily to caloric intake, and Shane essentially says so themselves. Giving testosterone equal billing with an active eating disorder as a cause is probably generous to the hormone.

What Shane got right: acknowledging the eating disorder, not overclaiming voice changes, accurately describing body hair growth as gradual and genetics-dependent, and framing all of this as personal experience rather than universal truth. That last part matters more than most viewers will realize.

What should you actually know?

Low-dose testosterone protocols for nonbinary and transmasculine patients are increasingly common, but clinical research specifically on subcutaneous low-dose regimens is still catching up to practice. Most of what we know is extrapolated from intramuscular dosing studies or from higher-dose transmasculine cohorts.

• Subcutaneous testosterone cypionate or enanthate at low doses produces lower peak serum levels and a flatter curve than IM injection, which some patients tolerate better emotionally (Spratt et al., 2017, JCEM).
• Irritability and mood instability in early testosterone therapy are real and documented. If you are starting testosterone and have a history of mood disorders, tell your prescriber before starting, not after symptoms appear.
• Eating disorders in transmasculine and nonbinary populations have elevated prevalence compared to cisgender peers (Diemer et al., 2015, LGBT Health). Testosterone does not treat an eating disorder, and the two should be managed in parallel with appropriate support.
• Voice strain during early masculinization is a real phenomenon. Working with a voice therapist during this period, not just waiting it out, can prevent longer-term strain injury.
• Sleep changes, including increased sleep need, have been reported anecdotally but are not well-characterized in controlled studies. If you are sleeping 10 or more hours and feel unrefreshed, that warrants a conversation with your provider, not just an assumption that testosterone is the cause.

The bottom line

Shane's update is one of the more honest and self-aware testosterone experience videos on TikTok right now. The symptom timeline is scientifically plausible, the self-disclosure around the eating disorder is clinically relevant and handled responsibly, and there is no overclaiming happening here. The only place the framing gets a little loose is around weight gain causation, but Shane themselves hedges appropriately. This is a personal update, not medical advice, and it reads like one.